Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Abstract Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the BE VIVID Japan patient subpopulation. Methods Global...

Full description

Bibliographic Details
Main Authors: Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-01-01
Series:Dermatology and Therapy
Subjects:
Absolute PASI
Active control
Bimekizumab
Japan subpopulation
Plaque psoriasis
Randomized controlled trial
Online Access:https://doi.org/10.1007/s13555-022-00883-y

Similar Items

Similar Items